September 25, 2016 2:19 PM ET

Biotechnology

Company Overview of Zafgen, Inc.

Company Overview

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate is the Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in patients with Prader-Willi syndrome; that has completed Phase II clinical trials to treat hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which has completed Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor that is...

175 Portland Street

4th Floor

Boston, MA 02114

United States

Founded in 2005

45 Employees

Phone:

617-622-4003

Key Executives for Zafgen, Inc.

Chief Executive Officer, President and Director
Age: 56
Total Annual Compensation: $450.0K
Chief Medical Officer
Age: 46
Total Annual Compensation: $367.5K
Compensation as of Fiscal Year 2015.

Zafgen, Inc. Key Developments

Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061

Zafgen, Inc. announced that the company has recently initiated dosing in the multiple ascending dose (MAD) cohorts of its ongoing Phase 1 clinical trial of ZGN-1061. The initiation of the MAD portion was triggered following a review of the initial safety and tolerability data from the first two cohorts of the single ascending dose (SAD) portion of the clinical trial. ZGN-1061 is a second-generation, differentiated MetAP2 inhibitor in development for severe and complicated obesity indications. The Phase 1 clinical trial is evaluating safety, tolerability, and weight loss efficacy over four weeks of treatment. The clinical trial includes a SAD portion, which will enroll up to 48 healthy subjects across up to six cohorts of single escalating doses of ZGN-1061. The clinical trial also includes a MAD portion, which is evaluating twice-weekly ZGN-1061 over four weeks in up to 24 obese subjects. Key elements of the clinical trial involve evaluation of the uptake and elimination of ZGN-1061, or pharmacokinetics, and evaluation of endpoints related to blood coagulation. The Company continues to expect top-line data from the clinical trial by the end of the first quarter of 2017. ZGN-1061, is a fumagillin-class MetAP2 inhibitor that originated from Zafgen's discovery program as part of a multi-year campaign to identify novel compounds that avoided limiting preclinical safety concerns observed with its first-generation MetAP2 inhibitor, beloranib, including teratogenicity and adverse effects on testicular function. The compound has metabolic efficacy, potency, and range of activity in animal models of obesity similar to beloranib, but displays highly differentiated safety properties and a reduced potential to impact thrombosis, supporting the value of the compound as a more highly optimized MetAP2 inhibitor.

Zafgen, Inc.(NasdaqGS:ZFGN) dropped from S&P Global BMI Index

Zafgen, Inc.(NasdaqGS:ZFGN) dropped from S&P Global BMI Index

Zafgen, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for the Period Ending December 31, 2016

Zafgen, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported loss from operations was $15.06 million against $17.610 million a year ago. Net loss was $15.03 million against $17.76 million a year ago. Basic and diluted loss per share was $0.55 against $0.66 a year ago. For the six months, the company reported loss from operations was $32.92 million against $30.85 million a year ago. Net loss was $32.76 million against $31.29 million a year ago. Basic and diluted loss per share was $1.20 against $1.19 a year ago. The company expects that its cash, cash equivalents and marketable securities balance will be greater than $125 million at December 31, 2016.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zafgen, Inc., please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.